Diagnostics and treatment of acromegaly Review article

Article Sidebar

PDF (Język Polski)


Published: Dec 30, 2011
Keywords:
acromegaly, growth hormone, diagnostic, treatment

Main Article Content

Marek Ruchała
Katedra i Klinika Endokrynologii, Przemiany Materii i Chorób Wewnętrznych Uniwersytetu Medycznego w Poznaniu
Ewelina Szczepanek-Parulska
Katedra i Klinika Endokrynologii, Przemiany Materii i Chorób Wewnętrznych Uniwersytetu Medycznego w Poznaniu
Ewa Komorska-Piotrowiak
Oddział Chorób Wewnętrznych Wojewódzkiego Szpitala Zespolonego w Lesznie

Abstract

Acromegaly is a chronic condition caused by excessive growth hormone secretion and secondary elevation of insulin-like growth factor 1 (IGF-1) concentration. Untreated or inappropriately treated disease results in development of severe complications including increased mortality, decreased average life expectancy and deteriorated quality of life. Constant stimulation of multiple tissues by growth factors in the course of the disease results in a significant increase in the prevalence of both benign and malignant tumors, of which the most frequent are colon, brain, breast, thyroid, uterus, prostate, kidney and skin lesions. All aforementioned complications are more prevalent in subjects with long-lasting and uncontrolled disease, hence an important role of early diagnosis, introduction of adequate treatment and well as careful follow-up in reduction of mortality and improvement of quality of life are discussed in the paper. Moreover, clinical picture of acromegaly, diagnostic procedures as well as up-to-date guidelines regarding therapy and monitoring of patients with this disease are concisely described.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Article Details

How to Cite
1.
Ruchała M, Szczepanek-Parulska E, Komorska-Piotrowiak E. Diagnostics and treatment of acromegaly. OncoReview [Internet]. 2011Dec.30 [cited 2024Nov.23];1(4(4):240-7. Available from: https://journalsmededu.pl/index.php/OncoReview/article/view/270
Issue
Vol 1 No 4(4) (2011)
Section
Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.

Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)

References

1. de Herder W.W.: Acromegaly and gigantism in the medical literature. Case descriptions in the era before and the early years after the initial publication of Pierre Marie (1886). Pituitary 2009; 12(3): 236-244.
2. Wass J.A.H.: Acromegaly – a handbook of history, current therapy and future prospects. Bioscientifica, Bristol 2009.
3. Szczeklik A.: Choroby wewnętrzne. Stan wiedzy na rok 2011. Wydawnictwo Medycyna Praktyczna, Kraków 2011.
4. Melmed S.: Medical progress: Acromegaly. N. Engl. J. Med. 2006; 355: 2558-573.
5. Nabarro J.D.: Acromegaly Clin. Endocrinol. 1987; 26: 481-512.
6. Gardner D., Shoback D.: Greenspan’s Basic&Clinical Endocrinology, Eight Edition. Mc Graw Hill Medical.
7. Fauci A., Braunwald E., Kasper D., Hauser S., Longo D., Jameson J., Loscalzo J.: Harrison´s Principles of Internal Medicine, Seventeenth Edition. McGraw-Hill 2008.
8. Puszczewicz M.: Reumatologia (Wyd. 1). Wydawnictwo Medycyna Praktyczna, Kraków 2010.
9. Scacchi M., Cavagnini F.: Acromegaly. Pituitary 2006; 9(4): 297-303.
10. Colao A., Ferone D., Marzullo P., Lombardi G.: Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr. Rev. 2004; 25: 102-152.
11. Colao A., Marek J., Goth M.I., Caron P., Kuhn J.M., Minuto F.M., Weissman N.J.: No greater incidence or worsening of cardiac valve regurgitation with somatostatin analog treatment of acromegaly. J. Clin. Endocrinol. Metab. 2008; 93: 2243-2248.
12. Antczak A.: Pulmonologia (Wyd. 1.). Medical Tribune Polska, Warszawa 2010: 477-478.
13. Grunstein R.R., Ho K.Y., Berthon-Jones M., Stewart D., Sullivan C.E.: Central sleep apnea is associated with increased ventilatory response to carbon dioxide and hypersecretion of growth hormone in patients with acromegaly. Am. J. Resp. Crit. Care Med. 1994; 150: 496-502.
14. Guilleminault C & van den Hoed J.: Acromegaly and narcolepsy. Lancet 1979; 2: 750-51.
15. Baum H., Lüdecke D.K., Herrmann H.D.: Carpal tunnel syndrome and acromegaly. Acta Neurochir. 1986; 83: 54-55.
16. Weir B.: Pituitary tumors and aneurysms: case report and review of the literature. Neurosurgery 1992; 30: 585-591.
17. Katznelson L., Kleinberg D., Vance M.L., Stavrou S., Pulaski K.J., Schoenfeld D.A., Hayden D.L., Wright M.E., Woodburn C.J., Klibanski A.: Hypogonadism in patients with acromegaly: data from the multi-centre acromegaly registry pilot study. Clin. Endocrinol. 2001; 54: 183-88.
18. Kaltsas G.A., Mukherjee J.J., Jenkins P.J., Satta M.A., Islam N., Monson J.P., Besser G.M., Grossman A.B.: Menstrual irregularity in women with acromegaly. J. Clin. Endocrinol. Metab. 1999; 84: 2731-35.
19. Kasayama S., Otsuki M., Takagi M., Saito H., Sumitani S., Kouhara H., Koga M., Saitoh Y., Ohnishi T., Arita N.: Impaired beta-cell function in the presence of reduced insulin sensitivity determines glucose tolerance status in acromegalic patients. Clin. Endocrinol. 2000; 52: 549-555.
20. Ruchala M., Skiba A., Gurgul E., Uruski P., Wasko R., Sowinski J.: The occurrence of thyroid focal lesions and a need for fine needle aspiration biopsy in patients with acromegaly due to an increased risk of thyroid cancer. Neuro Endocrinol. Lett. 2009; 30(3): 382-6.
21. Bałdys-Waligórska A., Krzentowska A., Gołkowski F., Sokołowski G., Hubalewska-Dydejczyk A.: The prevalence of benign and malignant neoplasms in acromegalic patients. Endokrynologia Polska 2010; 61(1): 29-34.
22. Renehan A.G., Bhaskar P., Painter J.E., O’Dwyer S.T., Haboubi N., Varma J., Ball S.G., Shalet S.M.: The prevalence and characteristics of colorectal neoplasia in acromegaly. J. Clin. Endocrinol. Metab. 2000; 85(9): 3417-24.
23. Ruchala M., Stangierska I., Gurgul E., Stangierski A., Fajfer J., Sowinski J.: The effect of octreotide treatment on somatic and psychological symptoms of acromegaly. Neuro Endocrinol. Lett. 2010; 31(2): 265-9.
24. Pantanetti P., Sonino N., Arnaldi G., Boscaro M.: Self image and quality of life in acromegaly. Pituitary 2002; 5: 17-19.
25. Furman K., Ezzat S.: Psychological features of acromegaly. Psychother. Psychosom. 1998; 67: 147-153.
26. Matta M.P., Couture E., Cazals L., Vezzosi D., Bennet A., Caron P.: Impaired quality of life of patients with acromegaly: control of GH/IGF-I excess improves psychological subscale appearance. Eur. J. Endocrinol. 2008; 158: 305-310.
27. Bolanowski M., Bar-Andziak E., Kos-Kudła B. et al.: Konsensus Polskiego Towarzystwa Endokrynologicznego. Przygotowanie analogami somatostatyny do leczenia operacyjnego akromegalii. Endokrynol. Pol. 2007; 58: 350-353.
28. Melmed S., Calao A., Barkan A. et al.: Guidelines for acromegaly management: an update. J. Clin. Endocrinol. Metab. 2009; 94: 1509-1517.
29. Gustina A., Chanson P., Bronstein M.D. et al.: A Consensus on Criteria for Cure of Acromegaly. J. Clin. Endocrinol. Metab. 2010; 95: 3141-3148.

Most read articles by the same author(s)